Amicus Therapeutics

Amicus Therapeutics

Verified
Discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases
Middlesex County United States (HQ)
Deals in the last 12 months undisclosed

Company information

Edit
Launch date
Employees
530 people
Ownership
Market cap
$5.3b
Net debt
$128m
Firm valuation
€4.8b (Public information from 2021)
Revenues, earnings & profits over time
USD20162017201820192020E2021E2022E
Revenues-36m91m182m261m321m462m
% growth--153 %100 %43 %23 %44 %
EBITDA-(438m)(325m)(299m)(214m)(154m)(84m)
% EBITDA margin-(1217 %)(357 %)(164 %)(82 %)(48 %)(18 %)
Profit-(284m)(349m)(356m)(255m)(190m)(84m)
% profit margin-(789 %)(384 %)(196 %)(98 %)(59 %)(18 %)
EV / revenue-59.5x17.9x12.0x19.7x16.6x11.4x
EV / EBITDA--5.0x-5.0x-7.3x-24.0x-34.5x-62.2x
  • Edit

Recent News about Amicus Therapeutics

Edit